BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX – Get Rating)’s stock price dropped 4% on Friday after an insider sold shares in the company. The stock traded as low as $7.64 and last traded at $7.66. Approximately 685,590 shares traded hands during mid-day trading, a decline of 76% from the average daily volume of 2,833,500 shares. The stock had previously closed at $7.98.Specifically, Director Machelle Sanders sold 4,000 shares of the business’s stock in a transaction on Thursday, June 15th. The shares were sold at an average price of $7.98, for a total transaction of $31,920.00. Following the completion of the sale, the director now directly owns 25,611 shares of the company’s stock, valued at $204,375.78. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Insiders own 5.00% of the company’s stock.
Analyst Upgrades and Downgrades
BCRX has been the subject of a number of research reports. Royal Bank of Canada reaffirmed a “sector perform” rating and issued a $10.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, March 14th. StockNews.com lowered shares of BioCryst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Friday, May 12th. JMP Securities reaffirmed a “market outperform” rating and issued a $16.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 22nd. Evercore ISI lowered their price objective on shares of BioCryst Pharmaceuticals from $13.00 to $10.00 and set an “outperform” rating for the company in a research note on Thursday, April 20th. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Wednesday, February 22nd. Four equities research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $15.00.
BioCryst Pharmaceuticals Trading Down 3.5 %
The company’s 50-day simple moving average is $8.19 and its 200 day simple moving average is $9.42.
BioCryst Pharmaceuticals (NASDAQ:BCRX – Get Rating) last released its quarterly earnings results on Wednesday, May 3rd. The biotechnology company reported ($0.28) EPS for the quarter, beating the consensus estimate of ($0.30) by $0.02. The firm had revenue of $68.80 million for the quarter, compared to analysts’ expectations of $71.44 million. During the same period in the previous year, the company posted ($0.40) earnings per share. The business’s quarterly revenue was up 37.9% compared to the same quarter last year. As a group, equities research analysts predict that BioCryst Pharmaceuticals, Inc. will post -1.03 EPS for the current year.
Hedge Funds Weigh In On BioCryst Pharmaceuticals
Hedge funds have recently modified their holdings of the stock. Fairfield Bush & CO. acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $34,000. State of Wyoming acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $35,000. Lazard Asset Management LLC acquired a new position in shares of BioCryst Pharmaceuticals during the first quarter valued at about $57,000. Advisory Services Network LLC increased its holdings in shares of BioCryst Pharmaceuticals by 46.3% during the first quarter. Advisory Services Network LLC now owns 4,740 shares of the biotechnology company’s stock valued at $40,000 after acquiring an additional 1,500 shares in the last quarter. Finally, Natixis acquired a new position in shares of BioCryst Pharmaceuticals during the fourth quarter valued at about $55,000. Institutional investors and hedge funds own 79.05% of the company’s stock.
BioCryst Pharmaceuticals Company Profile
BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.